XRCC6 and carcinoma: Carcinoma cell lines, with varying surface expression of Ku70/80, were pre-treated with 1 × 10−8 M of INCA-X IgG, an anti-Ku70/80 antibody, and then incubated with a SAP-anti-human IgG antibody (Hum-ZAP).